BCIQ Profiles

Company Profile ReportTarget Profile Report
0624 amyloid breakthrough
BioCentury & Getty Images

Regulation

FDA expediting two more anti-amyloid therapies for Alzheimer’s

Aducanumab decision already opening the door to approvals on Phase II data 

Aducanumab decision already opening the door to approvals on Phase II data .

Jun 25, 2021 | 1:33 AM GMT

After its accelerated approval of Biogen’s aducanumab, FDA is moving quickly to expedite development of two more anti-amyloid mAbs, with Lilly’s donanemab looking like it could be the first in the indication to receive approval based on Phase II data.

On Wednesday, FDA granted breakthrough designation to donanemab from Eli Lilly and Co. (NYSE:LLY) and lecanemab (BAN2401) from partners Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB). The designations were based on Phase II results demonstrating both therapies reduce amyloid plaques in the brain and may have clinical benefit. Both compounds are

Read the full 1339 word article

How to gain access

Continue reading with a
two-week free trial.